Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced the company has entered into a licensing and supply agreement with the Philippines pharmaceutical company UNILAB for its Adalimumab biosimilar, under which UNILAB will register and market the drug in the Philippines.

Mabwell’s Junmaikang is a biosimilar of Humira®, Junmaikang was approved by the China National Medical Products Administration (NMPA) in China for 8 indications: Rheumatoid arthritis, ankylosing spondylitis, Psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children, Crohn's disease in children.

UNILAB ranks number 1 in the ASEAN pharmaceutical industry according to IQVIA, and this strategic partnership will leverage UNILAB’s strength as the leader of Philippine pharmaceutical industry with significant manufacturing, registration, sales and marketing capabilities in the Philippines.

Mr. Huiguo Hu, the Board member and SVP of Mabwell, said: “Mabwell is pleased to partner with UNILAB to commercialize Adalimumab biosimilar in the Philippines, this collaboration will strengthen Mabwell’s presence in one of the promising markets in the ASEAN markets and represents the approval of our product quality and high standard of clinical data of our products. This partnership will also benefit the patients in the Philippines by providing high quality affordable biological medicines.”

Atty. Jose Maria Ochave, Senior Vice President of UNILAB, “Partnership with Mabwell is an integral part of our strategy to develop further our biologicals business in the Philippines. More than a contractual agreement, it is an embodiment of our shared commitment to the greater good, bringing affordable biological medicines to the patients of the Philippines. Our values of excellence, quality healthcare, and patient-centricity will be the driving force behind the success of this endeavor.”

About UNILAB, Inc.

UNILAB, Inc. is part of the UNITED LABORATORIES (UNITED) Group of Companies. UNITED is the no. 1 pharmaceutical company in the ASEAN region (i.e., the 10 member countries of the Association of Southeast Asian Nations) in terms of sales, with 14 pharmaceutical manufacturing facilities in the Philippines, Indonesia, Thailand, and Vietnam. In the Philippines, UNILAB, Inc. has 19.9% market share (IQVIA MAT data as of December 2022), with sales of USD 0.92 billion. They are present in the OTC and ethical segments, where they have market shares of 26.5% and 16.1%, respectively. Six of the top 10 OTC brands in the Philippines are UNILAB brands, and they also have their distribution operations that delivers goods in all relevant hospital, pharmacy, and supermarket channels nationwide.